Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Forefront Analytics LLC

Forefront Analytics LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 328 shares of the biopharmaceutical company’s stock after selling 16 shares during the period. Forefront Analytics LLC’s holdings in Regeneron Pharmaceuticals were worth $345,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in REGN. Aviso Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 28.1% in the second quarter. Aviso Wealth Management now owns 1,645 shares of the biopharmaceutical company’s stock valued at $1,729,000 after acquiring an additional 361 shares in the last quarter. Susquehanna Fundamental Investments LLC raised its stake in shares of Regeneron Pharmaceuticals by 1,719.2% in the second quarter. Susquehanna Fundamental Investments LLC now owns 23,286 shares of the biopharmaceutical company’s stock valued at $24,474,000 after acquiring an additional 22,006 shares in the last quarter. Lighthouse Investment Partners LLC raised its stake in shares of Regeneron Pharmaceuticals by 141.6% in the second quarter. Lighthouse Investment Partners LLC now owns 12,536 shares of the biopharmaceutical company’s stock valued at $13,176,000 after acquiring an additional 7,348 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of Regeneron Pharmaceuticals by 3.7% in the second quarter. Mackenzie Financial Corp now owns 57,964 shares of the biopharmaceutical company’s stock valued at $60,922,000 after acquiring an additional 2,074 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Regeneron Pharmaceuticals by 0.7% in the second quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock valued at $357,945,000 after acquiring an additional 2,270 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $1,042.69 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The stock’s 50-day moving average is $1,128.91 and its two-hundred day moving average is $1,035.02. The firm has a market cap of $114.95 billion, a price-to-earnings ratio of 30.80, a PEG ratio of 3.57 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the company posted $8.79 earnings per share. The business’s revenue was up 12.3% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Truist Financial reiterated a “buy” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,118.62.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold a total of 9,270 shares of company stock valued at $10,695,833 over the last quarter. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.